Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs

PHILADELPHIA, PA–(Marketwired – Feb 17, 2016) –
Medgenics, Inc. (NYSE MKT: MDGN)
Enrollment Initiated in Groundbreaking Non-interventional
Phenotype/Genotype Study of mGluR Mutations in ADHD IND Clearance Received for 22Q11.2 Deletion Syndrome Medgenics, Inc. (NYSE MKT: MDGN) today reported financial results for the three and twelve months ended December 31, 2015, as well as several key business and clinical development program highlights.

This entry was posted in Recent Developments. Bookmark the permalink.
Read Full Article »